Skip to content

US · HQH · ASSET MANAGEMENT

Abrdn Healthcare Investors (HQH) intrinsic value and stock valuation

$18.85as of 2026-11-21 · Mkt cap 1.29B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Abrdn Healthcare Investors DCF and intrinsic value

InvestorsCraft values HQH with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from HQH’s statements →

Abrdn Healthcare Investors Graham Number

Graham Number: $29.88d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Financial Services · Asset Management Philadelphia, PA 19103 teklacap.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$99.8M+62.1% 5y CAGRd
20142025
Net income
$98.6M-16.4% 5y CAGRd
20142025
Free cash flow
$0.00
20142025
Total equity
$1.09B+0.7% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$99.8M$10.8M$10.3M$8.27M$6.48M
Operating income$98.6M-$-220K-$-1.19M-$-3.67M-$-6.23M
Net income$98.6M$185M$56.3M-$-194.23M$155.2M
EPSd$1.84M$3.55M$1.14M-$-4.1M$3.42M
Operating cash flow$0.00$0.00$0.00$0.00$0.00
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow$0.00$0.00$0.00$0.00$0.00
Total assets$1.1B$1.06B$932.5M$926.3M$1.17B
Total debt$0.00$0.00$0.00$8.5M$11.3M
Net debt-$0.00-$0.00-$0.00$8.49M$11.3M
Total equity$1.09B$1.06B$931.3M$916.6M$1.16B
Cash and short-term investments$0.00$0.00$0.00$0.00$0.00
Income statement
20252024202320222021
Revenue$99.8M$10.8M$10.3M$8.27M$6.48M
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$99.8M$10.8M$10.3M$8.27M$6.48M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$1.14M$11M$11.5M$11.9M$12.7M
Other expenses$60K$0.00$0.00$0.00$0.00
Operating expenses$1.2M$11M$11.5M$11.9M$12.7M
Cost and expenses$1.2M$11M$11.5M$11.9M$12.7M
Interest income$1M$2.02M$620K$110K$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$220K$1.19M$3.67M$6.23M
Ebitda$98.6M$0.00$0.00$0.00$0.00
Operating income$98.6M-$-220K-$-1.19M-$-3.67M-$-6.23M
Total other income/expenses, net$0.00$185.2M$57.5M-$-190.56M$161.4M
Income before tax$98.6M$185M$56.3M-$-194.23M$155.2M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income$98.6M$185M$56.3M-$-194.23M$155.2M
Weighted average shares outstanding$53.6M$52.1M$49.4M$47.3M$45.4M
Weighted average diluted shares outstanding$53.6M$52.1M$49.4M$47.3M$45.4M
Balance sheet
20252024202320222021
Cash and short-term investments$0.00$0.00$0.00$0.00$0.00
Net receivables$2.54M$500K$6.85M$2.87M$4.05M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$2.61M$600K$39.6M$42.7M$12.4M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$1.08B$1.04B$824.7M$804.8M$1.07B
Total non-current assets$1.09B$1.06B$892.9M$883.6M$1.16B
Total assets$1.1B$1.06B$932.5M$926.3M$1.17B
Accounts payable$1.21M$0.00$0.00$0.00$0.00
Short-term debt$0.00$0.00$0.00$8.5M$11.3M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.21M$1.4M$1.15M$9.71M$15.6M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.22M$0.00$1.15M$0.00$15.6M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$3.43M$1.4M$1.15M$9.71M$15.6M
Common stock$560K$520K$490K$470K$450K
Retained earnings$101.6M$118M$5.97M$24.8M$303.1M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$1.09B$1.06B$931.3M$916.6M$1.16B
Total investments$1.09B$1.04B$824.7M$804.8M$1.07B
Total debt$0.00$0.00$0.00$8.5M$11.3M
Net debt-$0.00-$0.00-$0.00$8.49M$11.3M
Cash flow statement
20252024202320222021
Net income$98.6M$185M$56.3M-$-194.23M$155.2M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital$0.00$0.00$0.00$0.00$0.00
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities$0.00$0.00$0.00$0.00$0.00
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$0.00$0.00$0.00$0.00$0.00
Net change in cash$0.00$0.00$0.00$0.00$0.00
Cash at end of period$0.00$0.00$0.00$0.00$0.00
Operating cash flow$0.00$0.00$0.00$0.00$0.00
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow$0.00$0.00$0.00$0.00$0.00
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Abrdn Healthcare Investors

        Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. Abrdn Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.

        CEO
        Daniel R. Omstead
        Employees
        0
        Beta
        0.74

        Explore

        Frequently asked questions

        What is the intrinsic value of Abrdn Healthcare Investors (HQH)?

        Abrdn Healthcare Investors (HQH) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is HQH undervalued?

        HQH trades at a price of $18.85 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.